ALPHAMAB

Alphamab Oncology is a clinical-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biologics for cancer treatment. The company was established in 2015 as a spin-out from Suzhou Alphamab. It went public on the Main Board of the Hong Kong Stock Exchange on December 12, 2019, under the stock code 9966.

The company was founded by Dr. Ting Xu, who serves as Chairman and CEO. Dr. Xu founded the parent company, Suzhou Alphamab, in 2008 after a career in the US at biopharmaceutical companies including Biogen and Serono. His focus is on developing multifunctional antibodies and protein drugs with improved precision and efficacy.

Alphamab Oncology's business model is centered on its fully integrated, proprietary biologics platforms, which include technologies for bispecific antibodies, protein engineering, antibody-drug conjugates (ADCs), and single-domain antibodies. These platforms are used to create a differentiated and globally competitive product pipeline. A key product is Envafolimab (KN035), the world's first subcutaneously injectable PD-L1 inhibitor, which was approved in China in 2021. The pipeline also includes other candidates in various clinical trial stages, such as KN046 (a PD-L1/CTLA-4 bispecific antibody) and KN026 (an anti-HER2 bispecific antibody). The company's revenue is generated through product sales, and it engages in strategic collaborations and partnerships to advance its pipeline globally. For instance, it has collaboration agreements with ArriVent BioPharma and CSPC Pharmaceutical Group for the development and commercialization of its ADC products, which include upfront payments, potential milestone payments, and royalties.

The company operates primarily in the oncology market, developing therapies for various cancers, including solid tumors, non-small cell lung cancer, and HER2-positive breast cancer. Its manufacturing and R&D base is located in Suzhou Industrial Park, built to GMP standards to support both clinical and commercial scale production.

Keywords: biopharmaceuticals, oncology, antibody-drug conjugates, bispecific antibodies, cancer therapy, immunotherapy, protein engineering, clinical-stage, PD-L1 inhibitor, HER2, CTLA-4, Envafolimab, KN046, KN026, biologics platform, drug development, subcutaneous injection, biotherapeutics, single-domain antibody, solid tumors